Development of a pharmacodynamic model of murine malaria and antimalarial treatment with dihydroartemisinin

International Journal for Parasitology

Volumn 37, Issue 14, 2007, Pages 1569-1576

  Gibbons, Peter L ^a   Batty, Kevin T ^a   Barrett, P Hugh R ^b   Davis, Timothy M E ^b   Ilett, Kenneth F ^b,c  

^a CURTIN UNIVERSITY   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c PATHWEST LABORATORY MEDICINE   (Australia)

Author keywords

Dihydroartemisinin; Malaria; Mouse; Pharmacodynamics; Plasmodium berghei

Indexed keywords

DIHYDROARTEMISININ;

ANTIMALARIAL AGENT; DRUG DEVELOPMENT; HEMOPARASITE; MALARIA; POPULATION GROWTH; POPULATION MODELING; PROTOZOAN; RODENT;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; ERYTHROCYTE; IN VITRO STUDY; MALARIA; MALE; MOUSE; NONHUMAN; PARASITEMIA; PHARMACODYNAMICS; PLASMODIUM BERGHEI; SWISS WEBSTER MOUSE;

ANIMALS; ANTIMALARIALS; ARTEMISININS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROCYTE COUNT; ERYTHROCYTES; MALARIA; MALE; MICE; MICE, INBRED BALB C; PARASITEMIA; PLASMODIUM BERGHEI; SESQUITERPENES;

MURINAE; MUS; PLASMODIUM BERGHEI;

EID: 35148849536     PISSN: 00207519     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpara.2007.05.001     Document Type: Article

References (43)

1. Adam E., Pierrot C., Lafitte S., Godin C., Saoudi A., Capron M., and Khalife J. The age-related resistance of rats to Plasmodium berghei infection is associated with differential cellular and humoral immune responses. Int. J. Parasitol. 33 (2003) 1067-1078
2. Adjuik M., Babiker A., Garner P., Olliaro P., Taylor W., and White N. Artesunate combinations for treatment of malaria: meta-analysis. Lancet 363 (2004) 9-17
3. 2+ ATPase), tctp, mdr1, and cg10. Antimicrob. Agents Chemother. 50 (2006) 480-489
4. Ang K.K., Holmes M.J., and Kara U.A. Immune-mediated parasite clearance in mice infected with Plasmodium berghei following treatment with manzamine A. Parasitol. Res. 87 (2001) 715-721
5. Batty K.T., Ilett K.F., Edwards G., Powell S.M., Maggs J.L., Park B.K., and Davis T.M. Assessment of the effect of malaria infection on hepatic clearance of dihydroartemisinin using rat liver perfusions and microsomes. Br. J. Pharmacol. 125 (1998) 159-167
6. Bwijo B., Alin M.H., Abbas N., Wernsdorfer W., and Bjorkman A. Efficacy of artemisinin and mefloquine combinations against Plasmodium falciparum. In vitro simulation of in vivo pharmacokinetics. Trop. Med. Int. Health 2 (1997) 461-467
7. Cigel F., Batchelder J., Burns Jr. J.M., Yanez D., van der Heyde H., Manning D.D., and Weidanz W.P. Immunity to blood-stage murine malarial parasites is MHC class II dependent. Immunol. Lett. 89 (2003) 243-249
8. Cox F. Major animal models in malaria research: rodent. In: Wernsdorfer W.H., and McGregor I. (Eds). Malaria Principles and Practice of Malariology vol. 2 (1988), Churchill Livingstone, New York 1503-1543
9. Davis T.M., Karunajeewa H.A., and Ilett K.F. Artemisinin-based combination therapies for uncomplicated malaria. Med. J. Aust. 182 (2005) 181-185
10. Davis T.M., and Martin R.B. Clearance of young parasite forms following treatment of falciparum malaria in humans: comparison of three simple mathematical models. Epidemiol. Infect. 119 (1997) 61-69
11. Day N., Pham T., Phan T., Dinh X., Pham P., Ly V., Tran T., Nguyen T., Bethell D., Nguyan H., and White N. Clearance kinetics of parasites and pigment-containing leukocytes in severe malaria. Blood 88 (1996) 4694-4700
12. de Souza J.B., and Riley E.M. Cerebral malaria: the contribution of studies in animal models to our understanding of immunopathogenesis. Microbes Infect. 4 (2002) 291-300
13. Deharo E., Barkan D., Krugliak M., Golenser J., and Ginsburg H. Potentiation of the antimalarial action of chloroquine in rodent malaria by drugs known to reduce cellular glutathione levels. Biochem. Pharmacol. 66 (2003) 809-817
14. Fonseca L., Vigario A.M., Seixas E., and do Rosario V.E. Plasmodium berghei: selection of mefloquine-resistant parasites through drug pressure in mosquitoes. Exp. Parasitol. 81 (1995) 55-62
15. Garnham P. Rodent species of malaria parasites. In: Garnham P. (Ed). Malaria Parasites and Other Haemosporidia (1966), Blackwell, Oxford 431-475
16. Girault S., Delarue S., Grellier P., Berecibar A., Maes L., Quirijnen L., Lemiere P., Debreu-Fontaine M.A., and Sergheraert C. Antimalarial in-vivo activity of bis(9-amino-6-chloro-2-methoxyacridines). J. Pharm. Pharmacol. 53 (2001) 935-938
17. Gupta S., Thapar M.M., Mariga S.T., Wernsdorfer W.H., and Bjorkman A. Plasmodium falciparum: in vitro interactions of artemisinin with amodiaquine, pyronaridine, and chloroquine. Exp. Parasitol. 100 (2002) 28-35
18. Hien T.T., and White N.J. Qinghaosu. Lancet 341 (1993) 603-608
19. Hoshen M.B., Stein W.D., and Ginsburg H. Mathematical modelling of malaria chemotherapy: combining artesunate and mefloquine. Parasitology 124 (2002) 9-15
20. Janse C.J., Waters A.P., Kos J., and Lugt C.B. Comparison of in vivo and in vitro antimalarial activity of artemisinin, dihydroartemisinin and sodium artesunate in the Plasmodium berghei-rodent model. Int. J. Parasitol. 24 (1994) 589-594
21. Kremsner P.G., and Krishna S. Antimalarial combinations. Lancet 364 (2004) 285-294
22. Landau I., and Gautret P. Animal models: rodents. In: Sherman I.W. (Ed). Malaria: Parasite Biology, Pathogenesis and Protection (1998), American Society for Microbiology, Washington, DC 401-417
23. Li Q.G., Si Y.Z., Lee P., Wong E., Xie L.H., Kyle D.E., and Dow G.S. Efficacy comparison of intravenous artelinate and artesunate in Plasmodium berghei-infected Sprague-Dawley rats. Parasitology 126 (2003) 283-291
24. Lin A.J., Klayman D.L., and Milhous W.K. Antimalarial activity of new water-soluble dihydroartemisinin derivatives. J. Med. Chem. 30 (1987) 2147-2150
25. Loiseau P.M., and Nguyen D.X. Plasmodium berghei mouse model: antimalarial activity of new alkaloid salts and of thiosemicarbazone and acridine derivatives. Trop. Med. Int. Health 1 (1996) 379-384
26. Looareesuwan S., Davis T.M., Pukrittayakamee S., Supanaranond W., Desakorn V., Silamut K., Krishna S., Boonamrung S., and White N.J. Erythrocyte survival in severe falciparum malaria. Acta Trop. 48 (1991) 263-270
27. Looareesuwan S., Ho M., Wattanagoon Y., White N.J., Warrell D.A., Bunnag D., Harinasuta T., and Wyler D.J. Dynamic alteration in splenic function during acute falciparum malaria. N. Engl. J. Med. 317 (1987) 675-679
28. Mackenstedt U., Brockelman C.R., Mehlhorn H., and Raether W. Comparative morphology of human and animal malaria parasites. I. Host-parasite interface. Parasitol. Res. 75 (1989) 528-535
29. Murata K., Takano F., Fushiya S., and Oshima Y. Potentiation by febrifugine of host defense in mice against Plasmodium berghei NK65. Biochem. Pharmacol. 58 (1999) 1593-1601
30. Pedroni H.C., Bettoni C.C., Spalding S.M., and Dalla Costa T. Plasmodium berghei: development of an irreversible experimental malaria model in Wistar rats. Exp. Parasitol. 113 (2006) 193-196
31. Peters W. The chemotherapy of rodent malaria, XXII. The value of drug-resistant strains of Plasmodium berghei in screening for blood schizontocidal activity. Ann. Trop. Med. Parasitol. 69 (1975) 155-171
32. Peters W., and Robinson B.L. Malaria. In: Zak O., and Sande M. (Eds). Handbook of Animal Models of Infection: Experimental Models in Antimicrobial Chemotherapy (1999), Academic Press, London 757-773
33. Ronn A.M., Msangeni H.A., Mhina J., Wernsdorfer W.H., and Bygbjerg I.C. High level of resistance of Plasmodium falciparum to sulfadoxine-pyrimethamine in children in Tanzania. Trans. R. Soc. Trop. Med. Hyg. 90 (1996) 179-181
34. Rowe R.C., Sheskey P.J., and Owen S.C. Handbook of Pharmaceutical Excipients (2005), Pharmaceutical Press, London
35. Sadun E.H., Williams J.S., Meroney F.C., and Hutt G. Pathophysiology of Plasmodium berghei infection in mice. Exp. Parasitol. 17 (1965) 277-286
36. Sharma A., and Jusko W.J. Characteristics of indirect pharmacodynamic models and applications to clinical drug responses. Br. J. Clin. Pharmacol. 45 (1998) 229-239
37. Simpson J.A., Watkins E.R., Price R.N., Aarons L., Kyle D.E., and White N.J. Mefloquine pharmacokinetic-pharmacodynamic models: implications for dosing and resistance. Antimicrob. Agents Chemother. 44 (2000) 3414-3424
38. Stoltzfus R.J., Chwaya H.M., Albonico M., Schulze K.J., Savioli L., and Tielsch J.M. Serum ferritin, erythrocyte protoporphyrin and hemoglobin are valid indicators of iron status of school children in a malaria-holoendemic population. J. Nutr. 127 (1997) 293-298
39. Vennerstrom J.L., Arbe-Barnes S., Brun R., Charman S.A., Chiu F.C., Chollet J., Dong Y., Dorn A., Hunziker D., Matile H., McIntosh K., Padmanilayam M., Santo Tomas J., Scheurer C., Scorneaux B., Tang Y., Urwyler H., Wittlin S., and Charman W.N. Identification of an antimalarial synthetic trioxolane drug development candidate. Nature 430 (2004) 900-904
40. Walker D.J., Pitsch J.L., Peng M.M., Robinson B.L., Peters W., Bhisutthibhan J., and Meshnick S.R. Mechanisms of artemisinin resistance in the rodent malaria pathogen Plasmodium yoelii. Antimicrob. Agents Chemother. 44 (2000) 344-347
41. White N.J. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob. Agents Chemother. 41 (1997) 1413-1422
42. Xie L.H., Johnson T.O., Weina P.J., Si Y., Haeberle A., Upadhyay R., Wong E., and Li Q. Risk assessment and therapeutic indices of artesunate and artelinate in Plasmodium berghei-infected and uninfected rats. Int. J. Toxicol. 24 (2005) 251-264
43. Zhao Y., Hall I.H., Oswald C.B., Yokoi T., and Lee K.H. Antimalarial agents. III. Mechanism of action of artesunate against Plasmodium berghei infection. Chem. Pharm. Bull. (Tokyo) 35 (1987) 2052-2061